Key terms
About LABP
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LABP news
Apr 01
6:17am ET
Maintaining Hold Rating on Landos Biopharma Amid Acquisition by AbbVie and Limited Upside Potential
Apr 01
6:16am ET
Landos Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Apr 01
5:58am ET
This Biopharma Stock Outperformed MSTR and SMCI in March 2024
Mar 25
9:13am ET
Landos Biopharma’s Definitive Merger with AbbVie Subsidiary
Mar 25
9:00am ET
Landos Biopharma Inc trading resumes
Mar 25
8:35am ET
AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVR
Mar 25
8:34am ET
AbbVie to acquire Landos Biopharma got $20.42 per share in cash
Mar 25
8:32am ET
AbbVie to acquire Landos Biopharma for $20.42 per share in cash
Mar 25
8:25am ET
Landos Biopharma Inc trading halted, news pending
Mar 21
8:02am ET
Landos Biopharma reports Q4 EPS (99c) vs ($1.30) last year
No recent news articles are available for LABP
LABP Financials
Key terms
Ad Feedback
LABP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LABP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
